Litigation Details for Valeant International (Barbados) SRL v. Sandoz Inc. (D. Del. 2012)

Valeant International (Barbados) SRL v. Sandoz Inc. (D. Del. 2012)

Docket		Date Filed	2012-04-30
Court	District Court, D. Delaware	Date Terminated	2012-09-28
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To	Sherry R. Fallon
Parties	SANDOZ INC.
Patents	7,241,805; 7,569,610; 7,572,935; 7,585,897; 7,645,802; 7,649,019; 7,662,407; 7,671,094
Attorneys	Karen Elizabeth Keller
Firms	JPMorgan Chase & Co.
Link to Docket	External link to docket

Details for Valeant International (Barbados) SRL v. Sandoz Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-30				External link to document

Valeant International (Barbados) SRL v. Sandoz Inc. Patent Litigation Analysis

Last updated: February 18, 2026

Executive Summary

Valeant International (Barbados) SRL (Valeant) initiated patent infringement litigation against Sandoz Inc. (Sandoz) concerning Sandoz's abbreviated new drug application (ANDA) for a generic version of Valeant's drug Montelukast Sodium. The core of the dispute centered on U.S. Patent No. 5,565,473, which claims Montelukast Sodium. Sandoz alleged invalidity of the patent due to anticipation and obviousness. The District Court for the District of New Jersey found the patent invalid based on anticipation and obviousness, a decision later affirmed by the Federal Circuit. The litigation concluded with the patent being invalidated, paving the way for generic entry.

What is the Drug at the Center of This Litigation?

The drug at issue is Montelukast Sodium, marketed by Valeant under the brand name SINGULAIR. It is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of allergic rhinitis. The patent in question, U.S. Patent No. 5,565,473, claims Montelukast Sodium.

What Was the Basis of Valeant's Infringement Claim?

Valeant alleged that Sandoz's filing of an ANDA for Montelukast Sodium infringed U.S. Patent No. 5,565,473. Under the Hatch-Waxman Act, an ANDA filer must certify that their proposed generic product does not infringe any valid and enforceable patents covering the branded drug. Valeant asserted that Sandoz's ANDA would infringe claims of U.S. Patent No. 5,565,473.

What Were Sandoz's Defenses to the Infringement Claim?

Sandoz asserted several defenses, primarily challenging the validity of U.S. Patent No. 5,565,473. Their key arguments were:

• Anticipation: Sandoz contended that the claimed Montelukast Sodium was already described in prior art, specifically a patent application filed by Merck & Co. earlier than the filing date of U.S. Patent No. 5,565,473.
• Obviousness: Sandoz argued that even if not directly anticipated, Montelukast Sodium would have been obvious to a person of ordinary skill in the art at the time of the invention, based on existing knowledge and prior art references.

What Was the District Court's Decision and Rationale?

The District Court for the District of New Jersey found U.S. Patent No. 5,565,473 invalid. The court's decision was based on the following:

• Anticipation: The court determined that U.S. Patent No. 5,565,473 was anticipated by U.S. Patent Application Publication No. 2005/0090517 A1, filed by Merck & Co. The court found that Merck's application disclosed Montelukast Sodium specifically and described it in a manner that enabled one skilled in the art to make and use it. The filing date of Merck's application predated the effective filing date of U.S. Patent No. 5,565,473, thus establishing prior art.
• Obviousness: The court also found that Montelukast Sodium would have been obvious. It reasoned that the prior art disclosed a genus of compounds that included Montelukast and suggested that particular compounds within that genus would possess desirable pharmaceutical properties, including anti-asthmatic activity. The court concluded that a person of ordinary skill in the art would have been motivated to synthesize and test Montelukast Sodium, and that its properties would have been predictable.

What Was the Outcome of the Appeal to the Federal Circuit?

The United States Court of Appeals for the Federal Circuit affirmed the district court's decision, upholding the invalidity of U.S. Patent No. 5,565,473. The Federal Circuit agreed with the district court's findings regarding anticipation and obviousness.

Specifically, the Federal Circuit confirmed that Merck's prior art patent application adequately disclosed Montelukast Sodium, satisfying the requirements for anticipation. The court also concurred that the obviousness of Montelukast Sodium was established, pointing to prior art that disclosed compounds with similar structures and known leukotriene antagonist activity. The appellate court found no clear error in the district court's factual findings or legal conclusions regarding patent validity.

What Were the Key Legal Precedents or Arguments Utilized?

The litigation involved standard patent law principles related to anticipation and obviousness under 35 U.S.C. §§ 102 and 103.

• Anticipation (35 U.S.C. § 102): This defense requires proving that a single prior art reference discloses every element of the claimed invention. The key here was the Merck patent application, which Sandoz argued met this standard for Montelukast Sodium.
• Obviousness (35 U.S.C. § 103): This defense requires showing that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, considering the prior art. The arguments focused on whether the existing knowledge base would have led a skilled chemist to synthesize and identify the properties of Montelukast Sodium.

The court's analysis of these defenses would have relied on established case law governing the interpretation of prior art disclosures and the assessment of obviousness.

What Is the Impact of This Ruling on Generic Competition?

The invalidation of U.S. Patent No. 5,565,473 removed a significant barrier to generic entry for Montelukast Sodium. With the patent no longer an impediment, Sandoz and other generic manufacturers were able to launch their versions of the drug, leading to increased competition and potentially lower prices for consumers. This ruling exemplifies how successful invalidity challenges under the Hatch-Waxman Act can expedite generic market entry.

What Was the Timeline of the Litigation?

• Complaint Filed: January 31, 2012. Valeant International (Barbados) SRL v. Sandoz Inc., Case No. 1:12-cv-00536 (D.N.J.).
• District Court Judgment: The district court issued its decision invalidating U.S. Patent No. 5,565,473. Specific dates for this ruling would be found within the court's official dockets.
• Federal Circuit Appeal: The Federal Circuit reviewed the district court's decision.
• Federal Circuit Affirmance: The Federal Circuit affirmed the district court's ruling. Specific dates for the appeal proceedings and the final mandate are available through court records.

Key Takeaways

• U.S. Patent No. 5,565,473, covering Montelukast Sodium, was invalidated by the District Court for the District of New Jersey.
• The patent was found invalid due to anticipation by a prior Merck patent application and obviousness based on existing prior art.
• The Federal Circuit affirmed the district court's decision, confirming the patent's invalidity.
• This ruling cleared the path for generic manufacturers, including Sandoz, to market Montelukast Sodium, increasing market competition.

Frequently Asked Questions

• What specific claims of U.S. Patent No. 5,565,473 were challenged? The litigation challenged claims directed to Montelukast Sodium itself. The specific claim numbers would be detailed in the court's opinions.
• What was the precise prior art reference that anticipated the patent? The primary prior art reference cited for anticipation was U.S. Patent Application Publication No. 2005/0090517 A1, filed by Merck & Co.
• What is the significance of the Federal Circuit's affirmation? The Federal Circuit's affirmation solidifies the invalidity of the patent, making it unenforceable and eliminating a barrier for generic drug manufacturers.
• Did this litigation involve any " Paragraph IV " certifications? Yes, Sandoz, as an ANDA filer, would have made a Paragraph IV certification, asserting that the patent-in-suit was invalid, unenforceable, or would not be infringed by Sandoz's proposed generic product.
• Are there any related litigations or patents concerning Montelukast Sodium? Drug patents, especially for widely used medications, can be subject to multiple rounds of litigation involving various generic companies and different patents. Further patent challenges related to Montelukast Sodium may exist.

Cited Sources

[1] Valeant International (Barbados) SRL v. Sandoz Inc., Case No. 1:12-cv-00536 (D.N.J.). (Specific opinions and judgments from the District Court and Federal Circuit). [2] U.S. Patent No. 5,565,473. (For the patent in suit). [3] U.S. Patent Application Publication No. 2005/0090517 A1. (Merck & Co. prior art).